Boston Pharma Plays Catch Up To Akero, 89bio In MASH

 
• By Joseph Haas
  
NASH liver
Boston Pharma is trying to catch up in the FGF21 analog class in MASH • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Therapy Areas